Episode notes
This week, we have a conversation with Lisa Guerrettaz, executive director, Pharmacology and Translational Science at Artiva Biotherapeutics; and Avacta Therapeutics’ CEO Christina Coughlin.
Times:
04:12 Artiva Biotherapeutics
21:30 Avacta Therapeutics
Artiva Biotherapeutics
Artiva Biotherapeutics is a clinical‑stage cell therapy company developing off‑the‑shelf (allogeneic) natural killer (NK) cell therapies for autoimmune diseases and cancer. Headquartered in San Diego and founded in 2019, the company was created as a spin‑out from GC Cell (formerly GC Lab Cell) in South Korea, alongside a strategic partnership granting Artiva exclusive rights (outsid ...
Keywords
biotechbiotechnologycancernk cellsAvacta TherapeuticsArtiva Biotherapeutics